drugset / Trial / NCT05798546
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
Phase 1
Unknown
21 enrolled
BGI, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety of Neo-T in the treatment of advanced solid tumors. The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in the treatment of advanced solid tumors.
Timeline
- Start
- 2022-09-28
- Primary completion
- 2023-09
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NEOTETRAZOLIUM | Cell therapy | 1.2e+09 cells | Intravenous |
| Subject | NEOTETRAZOLIUM | Cell therapy | 2.4e+09 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 500000 iu | Subcutaneous |